PDF

Download this practical reference sheet on the administration, monitoring, and common adverse events of commonly used IBD treatments.
Format: Adobe Acrobat (.pdf)
File size: 84 KB
Date posted: 12/12/2016
  • Biosimilars: Addressing Uncertainties With a New Drug Class

    Kenneth G. Saag MD, MSc - 3/13/2017    2 comments / Last Comment: 4/24/2017
    Biosimilars promise increased access and decreased prices for patients in need of expensive biologics. However, as with any new category of drug, biosimilars face some uncertainties. Here’s my take.
  • Key Considerations for Using Biosimilars in IBD

    David T. Rubin MD - 6/6/2017    1 comment / Last Comment: 6/22/2017
    The role of biosimilars in the setting of IBD is growing. Here’s my take on some of the key things you need to consider when using these agents.